The effect of mavacamten therapy on the risk of sudden cardiac death among patients with hypertrophic obstructive cardiomyopathy

11 May 2026 (13:30 - 14:15)

Organised by:

Abstract

Slides

Sign in for access options

About the speaker

Doctor Fanni Banfi-Bacsardi

Gottsegen National Cardiovascular Center, Budapest (Hungary)

6 More presentations in this session

Presentation thumbnail

Artificial intelligence-enabled electrocardiography to predict left ventricular ejection fraction decline in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten

Doctor J. Choi (Seongnam, KR)

Abstract Slides

Presentation thumbnail

Comparison of transcoronary ablation of septal hypertrophy (TASH) and Mavacamten treatment in patients with obstructive hypertrophic cardiomyopathy: a single-center study

Doctor J. Koelemen (Heidelberg, DE)

Abstract Slides

Presentation thumbnail

No increase in arrhythmia burden following aficamten treatment in obstructive hypertrophic cardiomyopathy: extended ambulatory electrocardiogram analysis from FOREST-HCM

Doctor E. Rowin (Burlington, US)

Abstract Slides

Presentation thumbnail

Evaluation of the hypothetical risk of sudden cardiac death in obstructive HCM patients treated with mavacamten using the HCM Risk-SCD score

Doctor R. Esculudes Dos Santos Ferrao Gomes (Lisboa, PT)

Abstract Slides

Presentation thumbnail

Real-world individual patient-level analysis for mavacamten in obstructive hypertrophic cardiomyopathy: multi-domain response, safety and cyp2c19 genotype effects

Doctor P. Zwetsloot (Rotterdam, NL)

Abstract Slides

Access the full session

Session thumbnail

Hypertrophic obstructive cardiomyopathy: treatment, monitoring, and outcomes

The Event

Event poster

Heart Failure 2026

11 May 2026 13:30 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources